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Abstract
Background: Vascular endothelial growth factor receptor-2 (VEGFR2) plays a pivotal role in angiogenesis by
eliciting vascular endothelial cell growth when bound to VEGF, a powerful pro-angiogenic ligand. While Vegf and
Vegfr2 are expressed throughout gestation, the latter third of gestation in mice is characterized by a marked
increase in fetoplacental angiogenesis. Thus, the objective of this study was to determine the feasibility of
monitoring fetoplacental Vegfr2 gene activity non-invasively using a Vegfr2-luc reporter transgenic mouse and
bioluminescent imaging.
Methods: Imaging parameters were optimized using two wild-type (WT) females, bearing Vegfr2-luc fetuses. Then,
seven WT females, bred to Vegfr2-luc males, were imaged from gestational day (GD) 12 to 18 to determine the
usefulness of the Vegfr2-luc mouse as a model for studying fetoplacental Vegfr2 activity during pregnancy. Semi-
quantitative RT-PCR of Vegfr2 was also performed on whole fetoplacental units during this time. Additionally,
resultant neonates were imaged at postnatal day (PND) 7, 14 and 21 to monitor Vegfr2 activity during post-natal
development.
Results: Fetoplacental Vegfr2 gene activity was detected as light emissions beginning on GD 12 of gestation and
increased throughout the imaging period (P < 0.05), and this paralleled the Vegfr2 mRNA data obtained from
RT-PCR analysis. A decline in fetoplacental light emissions was associated with a poor pregnancy outcome in one
pregnancy, indicating that this approach has potential use for studies monitoring pregnancy well being.
Additionally, neonatal Vegfr2 activity was detected at PND 7, 14 and 21 but declined with time (P < 0.0001).
Conclusions: In utero fetoplacental Vegfr2 gene activity was monitored longitudinally in a quantitative manner
using a luciferase reporter gene and bioluminescent imaging during the latter third of gestation. This study
demonstrates the feasibility of using the Vegfr2-luc mouse to monitor late gestation fetoplacental angiogenic
activity under normal and experimental conditions. Additionally, neonatal Vegfr2 gene activity was monitored for
three weeks postpartum, allowing continuous monitoring of Vegfr2 activity during the latter third of gestation and
postnatal development within the same animals.
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Angiogenesis is the process by which new vasculature
develops from preexisting vascular structures, and vascular
endothelial growth factor A (VEGFA) and its cell-surface
receptor, vascular endothelial growth factor receptor
2 (VEGFR2), are two proteins that are vital for this pro-
cess. As a pro-angiogenic factor, VEGFA has been
described as the most potent stimulator of angiogenesis
while VEGFR2 is considered to be the primary receptor by
which VEGFA elicits its pro-angiogenic effects, including
the stimulation of endothelial cell growth in developing
tissues[1,2]. While Vegf and Vegfr2 expression is a hall-
mark process of angiogenesis during normal wound heal-
ing and tumor development, transcription of Vegf and
Vegfr2 is also critical for pregnancy success [3-9].
Recent advances in bioluminescent imaging technol-
ogy have allowed real-time monitoring of gene expres-
sion in vivo using transgenic animal models. In these
models, a light producing enzyme, such as firefly lucifer-
ase, is used as a reporter gene by incorporating it in the
animal genome so that its expression is induced when-
ever the gene of interest is transcriptionally active.
When luciferin, the substrate for luciferase, is adminis-
tered, oxidation occurs releasing energy in the form of
light which is proportional to the amount of gene activ-
ity. By allowing real-time measurements, these models
allow gene expression to be studied within the physiolo-
gical parameters of the living animal system [10]. Addi-
tionally, by reducing the need for numerous end-point
measurements, which usually involve sacrificing animals
to obtain tissue samples, fewer animals are needed to
monitor physiological events over time in longitudinal
studies [10] allowing the targeting of specific time points
for further end-point analysis. In 2004, Zhang and col-
leagues [11] utilized a transgene comprised of a murine
Vegfr2 promoter region cloned upstream from the luci-
ferase gene to create founder FVB/N - Tg(Vegfr2-luc) -
Xen mice (Vegfr2-luc), and recently, our laboratory has
employed the use of this transgenic mouse model to
study the activity of Vegfr2 in wound healing studies
[10,12]. When Vegfr2 is transcriptionally activated, luci-
ferase is also transcribed, allowing Vegfr2 expression
activity to be monitored non-invasively and quantita-
tively in real-time using imaging equipment that is
highly sensitive to low-emitting light.
While several studies describe the use of this mouse
model to monitor Vegfr2 expression during wound heal-
ing [10-14], there is no information in the literature
describing its use to monitor fetoplacental Vegfr2 activity
longitudinally in vivo. Therefore, in this paper, we
describe a murine pregnancy model, utilizing the Vegfr2-
luc mouse, which allows real-time monitoring of fetopla-
cental Vegfr2 gene activity using bioluminescent imaging.
Methods
Animals
Care and use of animals utilized in this study were con-
ducted in accordance with and under the approval of the
Institutional Animal Care and Use Committee of Missis-
sippi State University. Homozygous Vegfr2-luc males were
purchased from Caliper Life Sciences, Inc. (Hopkinton,
MA, USA), while wild type (WT) FVB/N females were
obtained from an in-house colony derived from two ven-
dors (The Jackson Laboratory Bar Harbor, ME, USA;
Charles River Laboratories International, Inc. Wilmington,
MA, USA). Males were caged individually and females in
groups of four to five per cage until paired for breeding,
after which bred females were housed individually. All ani-
mals were housed in an environmentally controlled room
set at 22°C with a 12 h light/12 h dark cycle and allowed
ad-libitum access to a phytoestrogen and alfalfa free diet
(Purina Test Diet, Richmond, IN, USA) and water. In
order to assess fetoplacental Vegfr2-luc expression, it was
necessary to breed homozygous Vegfr2-luc males to WT
FVB/N females so that only fetoplacental tissues would
express luciferase under the control of the cloned Vegfr2
promoter.
Optimization of imaging parameters
Due to the absence of information describing a Vegfr2-
l u cp r e g n a n c ym o d e l ,ap r e l i m i n a r ys t u d yw a sp e r -
formed with two pregnant WT females, bred to
Vegfr2-luc males, to determine the optimal imaging
parameters. Females were checked daily following pair-
ing with males, and the day on which a vaginal plug
was observed was designated as gestational day (GD) 1.
To avoid inferring with embryo implantation[15], ima-
ging was not performed until GD 6, at which time the
two females were imaged daily until GD 18 using the
IVIS 100 Imaging System (Caliper Life Sciences, Inc.
Hopkinton, MA, USA). Briefly, mice were anesthetized
with isoflurane (1.5 to 3.0%) and injected intraperito-
neally (i.p.), as recommended, in the lower left abdom-
inal quadrant with luciferin (150 mg/kg; Caliper Life
Sciences, Inc.) suspended in Dulbecco’s phosphate buf-
fered saline (15 mg/ml). Additionally, the abdominal
region of the mice was shaven to reduce the effects of
hair on light scattering and/or absorption. Previously,
dermal wound healing studies utilizing the Vegfr2-luc
mouse, reported that optimal luciferase activity for
imaging purposes occurred 10 minutes after luciferase
administration [10,11]; however, the time required for
luciferin to traverse the maternal vasculature and
arrive at the fetoplacental tissues was unknown. There-
fore, mice were imaged for five minutes at 10, 15, 20,
and 25 minutes post luciferin injection to determine
the optimal time needed for luciferin distribution.
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mal signal intensity was detected 20 minutes post luciferin
injection but was not detected prior to GD 12 at which
time, light emissions were consistently above background
signal. Additionally, i.p. injections in the lower left abdom-
inal region resulted in bruising over the injection site
which may interfere with accurate signal acquisition from
the fetoplacental tissues. Therefore, a subcutaneous (s.c.)
luciferin injection in the dorsal neck region was chosen as
an alternate site for luciferin delivery in subsequent mice
given the similar luciferin distribution kinetic characteris-
tics between both methods [16].
Bioluminescence imaging of pregnant and neonatal mice
After imaging optimization, we proceeded to determine
the usefulness of the Vegfr2-luc mouse as model for
quantitative, longitudinal and real-time study of fetopla-
cental Vegfr2 gene activity during pregnancy. Seven WT
females bred to Vegfr2-luc males were housed individu-
ally, and weights were recorded daily from GD 1 to 18 as
an indicator of fetal growth. From GD 12 to 18 of preg-
nancy, bred females were imaged utilizing the optimized
parameters determined from the preliminary study.
Briefly, mice were anesthetized with isoflurane (1.5 to
3.0%), and then the abdominal region was shaven fol-
lowed by administration of a luciferin (s.c.; 150 mg/kg
BW) in the dorsal neck region. Twenty minutes after
luciferin administration, mice were imaged for five min-
utes ventral side up using the IVIS 100 Imaging System
while maintained under isoflurane (1.5 to 3.0%) anesthe-
sia. Imaging terminated on GD 18 to prevent interfering
with parturition which averaged 19.5 days post breeding
in our colony.
In addition to the pregnant mice, pups (n = 27) from
six pregnancies were imaged on post-natal day (PND) 7,
14, and 21 to evaluate Vegfr2 gene activity as a means of
assessing post natal angiogenesis. Imaging parameters for
neonatal mice were adapted from Zhang and colleagues
[11]. Briefly, pups were anesthetized with isoflurane (1.5
to 3.0%), administered luciferin (s.c.; 150 mg/kg BW) in
the dorsal neck region, and subsequently imaged ven-
trally for two minutes using the IVIS 100 Imaging System
10 minutes post injection.
Image analysis
All images were analyzed using Living Image
® 2.50 soft-
ware (Caliper Life Sciences, Inc. Hopkinton, MA, USA).
Measurements were made by drawing regions of interests
(ROI) on the bioluminescent images. For the pregnant
females, a 4.25 cm × 5.5 cm primary ROI was drawn, cov-
ering the abdominal region of the animal being measured
(Figure 1). In addition, a smaller ROI (1.5 cm × 1.9 cm)
was drawn and placed on the ventral neck region to obtain
a background measurement for each animal to correct for
any autoluminescence that may originate from sources
such as chemiluminescent metabolic processes [17]. The
light emissions from the background ROI were subtracted
from the light emissions from the primary ROI, and these
measurements were expressed as calibrated units of
photons per second (p/s). The data for the pregnant
females are presented as total light emissions (p/s) and as
light emissions corrected for fetoplacental mass (p/s/g),
which was obtained by dividing the total light emissions
for each day by the amount of weight gain relative to the
initial body weight recorded on GD 1. Because the entire
body of the pups expressed light, driven by the cloned
Vegfr2 promoter, a background ROI could not be drawn.
Measurements were corrected for the average pup weight
of each litter and expressed as calibrated units of photons
per second per gram (p/s/g).
RT-PCR analysis of Vegfr2 mRNA expression
Four additional WT females were bred to Vegfr2-luc
males. At each time point, GD 12, 14, 16, and 18, one
female was imaged using the optimized imaging proce-
dures to detect luciferase activity. Following imaging,
females were sacrificed via cervical dislocation, and indivi-
dual fetoplacental units (FPU’s) were collected, imaged,
and then frozen at -80°C until further analysis. Total RNA
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Figure 1 Analysis of bioluminescent images acquired from WT
females bearing Vegfr2-luc fetuses. Images were analyzed using
Living Image
® 2.50 software. A 4.25 cm × 5.5 cm primary ROI was
drawn over the abdominal region, followed by a 1.5 × 1.9 cm
background ROI over the ventral neck region to correct for
autoluminescence. The color scheme represents the pseudo color
scale applied to the image, with the red colors indicating the
greatest light emissions and the purple colors representing the least
amount of light emissions.
Greene et al. Reproductive Biology and Endocrinology 2011, 9:51
http://www.rbej.com/content/9/1/51
Page 3 of 9was extracted from three whole FPU’s at each time point
using Trizol reagent (Invitrogen Co., Carlsberg, CA, USA).
RNA was quantified using a NanoDrop 1000 Spectrophot-
ometer (Thermo Scientific, Wilmington, DE, USA) and
reverse-transcribed into cDNA (RETROScript, Ambion,
Austin, TX). Table 1 details the primer pairs’ characteris-
tics. The PCR conditions were as follows: 5 min at 95°C;
28 cycles of 30 sec at 95°C, 90 sec at 58°C, and 30 sec at
72°C; followed by a final extension of 10 min at 68°C. PCR
products were resolved on 1.0% agarose gel stained with
GelStar Nucleic Acid Stain (Lonza Walkersville Inc.,
Walkersville, MD, USA), and band intensity was deter-
mined using Image J 1.44c software (NIH Image). Vegfr2
gene expression data are indicated as relative expression
to b-actin.
Statistical analysis
One bred female was excluded from the analysis due to a
failed pregnancy. Data were compared among days of
gestation for the pregnant females (n = 6) and among days
post-partum for pups (n = 27) using ANOVA. RT-PCR
data were also analyzed using ANOVA. Least square
means were calculated and separated using Fisher’sl e a s t
significant difference when the P-value from the ANOVA
was less than 0.05. Least square means were considered to
be significantly different at a value of P ≤ 0.05. Only biolu-
minescent imaging data from GD 12, 14, 16, and 18 were
used in the final statistical analysis as there were no daily
significant changes from GD 12 to GD 17. Data are pre-
sented as least square means ± standard error of the mean.
Results and Discussion
In vivo monitoring of fetoplacental Vegfr2 activity
Bioluminescent imaging of WT females, bearing Vegfr2-
luc fetuses, proved to be effective for monitoring fetopla-
cental Vegfr2 activity during the latter third of gestation
in a quantitative manner. Minimal signal was detected on
GD 12 in one of the six mice, while the other five mice
produced a strong signal. Beginning on GD 13 and conti-
nuing throughout the imaging period, all six mice pro-
duced a strong signal, representing fetoplacental Vegfr2
transcriptional activity. The described approach is one
that utilizes a WT female bred to a Vegfr2-luc male. In
contrast, utilizing a Vegfr2-luc female bred to a Vegfr2-
luc male would not allow fetoplacental light emissions to
be discriminated from light emissions originating from
maternal tissues, such as the uterus, which expresses
Vegfr2 during gestation [18] or ovarian angiogenesis
from vascularized corpus lutea [19]. The advantage of
utilizing a WT female is that background signal originat-
ing from maternal tissues is eliminated. This allows feto-
placental light emissions to be monitored, with large
signal to background ratios, since the only tissues bearing
the Vegfr2-luc transgene are those of fetal origin.
Previous studies utilizing the Vegfr2-luc mouse admi-
nistered luciferin with an i.p. injection given in the ani-
mal’s lower left abdominal quadrant [10-12]; however,
in our preliminary work, we observed that this method
of injection caused bruising at the injection site. This
injection method was abandoned because the pooling of
blood at the bruising site may interfere with the trans-
mission of light through the tissue [20]. Additionally,
since the uterus was rapidly expanding during this time,
penetrating the uterus with an i.p. injection became a
concern. Given these considerations, it was determined
that an s.c injection in the dorsal neck region may be
more appropriate for pregnant mouse model studies.
Subcutaneous injection proved to be a reliable and
repeatable method for luciferin administration, consis-
tent with previous studies which determined that s.c.
luciferin administration avoids potential misadministra-
tion associated with i.p. luciferin administration while
providing similar light emission yields and luciferin dis-
tribution kinetics [16].
Preliminary observations also revealed that 20 minutes
post luciferin injection yielded optimal signal intensity
for imaging purposes. Wound healing studies reported
optimal luciferase activity 10 minutes after luciferin
administration when using the Vegfr2-luc mouse [10,11];
however, in our preliminary work, waiting ten minutes
post-luciferin administration did not provide adequate
time for luciferin to disperse through the fetoplacental
tissues. It is likely that additional time is needed for luci-
ferin to traverse the maternal vasculature and be deliv-
ered to the fetoplacental tissues as compared to the time
needed to deliver luciferin to dorsal, dermal skin wounds.
Utilizing the optimized imaging parameters from the pre-
liminary study, quantitative differences in total light emis-
sions were found during the imaging period (Figure 2a;
P < 0.0001). Total light emissions on GD 12 and 14 did not
Table 1 Primer sequences and characteristics
Gene GenBank Acc. #, (NCBI) Primer sequences (5’-3’) Melt T (°C) Amplicon size (bp)
Vegfr2 NM_010612.2 S: CTTGCAGGGGACAGCGGGAC 59.7 314
AS: AATCGACCCTCGGCAGGGGA 59.3
Β-actin NM_007393.3 S: TACAATGAGCTGCGTGTGGCCC 59.7 257
AS: AGGATGGCGTGAGGGAGAGCAT 59.5
S, Sense; AS, Anti-sense.
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Page 4 of 9differ (P > 0.05) but were less (P < 0.05) than the amount of
light emissions detected on GD 16 and 18. Additionally,
total light emissions on GD 18 were significantly greater
(P < 0.05) than light emissions on GD 12, 14, and 16.
Accounting for fetoplacental mass, quantitative differences
in light emissions were also found (Figure 2b; P = 0.0004).
There were no differences (P > 0.05) in light emissions
between GD 12 and 14 or between GD 14 and 16. How-
ever, light emissions on GD 16 were greater (P < 0.05) than
light emissions on GD 12, and light emissions on GD 18
were greater (P < 0.05) than light emissions on GD 12, 14,
and 16, indicating that fetoplacental Vegfr2 gene activity
was greatest on GD 18. In addition to the quantitative data,
qualitative data (Figure 2c) also depicts an increase in light
emissions occurring during this time period. Moreover, in
vivo imaging of the pregnant dam (Figure 3a), followed by
ex vivo imaging of the gravid uterus (Figure 3b) and indivi-
dual FPU (Figure 3c) further revealed that the light emis-
sions were originating from fetoplacental tissues.
Detection of light emissions during the latter third of
gestation indicated that Vegfr2 was transcriptionally
active in fetoplacental tissues during this timeframe. It
has been previously reported that light emissions were
associated with Vegfr2 expression and angiogenesis
when the Vegfr2-luc mouse was used to study dermal
wound healing [10,11], and indeed, semi-quantitative
RT-PCR analysis, in the current study, confirmed that
Vegfr2 mRNA was present in fetoplacental tissues and
increased relative to b-actin (P < 0.05; Figure 3d). This
is consistent with the bioluminescent data and other
reports detailing an increase in Vegf mRNA during this
time [21]. Moreover, end-point measurements have
revealed that Vegfr2 is expressed as early as GD 7 dur-
ing murine pregnancy and is continually expressed
throughout gestation in fetal and placental tissues
[4,22,23]. The current data indicate the ability to moni-
tor fetoplacental Vegfr2 activity in real time and over
time in vivo during the latter third of gestation using a
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Figure 2 In vivo bioluminescent imaging of fetoplacental Vegfr2 activity. Quantitative differences in light emissions (p/s) were found during
the seven day imaging period (P < 0.05). (a) Comparing gestational day (GD) 12 to 18, total light emissions (p/s) increased by approximately
23-fold (P = 0.0006). The insert illustrates the increase in maternal body weight (P = 0.0008) occurring during this period, indicating fetoplacental
growth. (b) Light emissions corrected for fetoplacental mass (p/s/g) also increased by approximately 9-fold (P < 0.0001) during this time.
(c) Additionally, the images demonstrate qualitative monitoring of fetoplacental Vegfr2 gene activity in a complete set of images chosen from a
representative animal.
a,b,c means without a common superscript differ (P ≤ 0.05).
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Page 5 of 9luciferase reporter gene and bioluminescent imaging
technology. Quantitative differences in Vegfr2 activity
were detected which further suggests the usefulness of
this approach for obtaining meaningful data regarding
changes in fetoplacental Vegfr2 activity under experi-
mental conditions.
Previous reports have revealed that the latter third of
gestation in mice is characterized by a marked increase
in the amount of fetoplacental vasculature and fetal
growth [24-26]. In the current study comparing GD 12
to GD 18, there was a 23-fold increase (P < 0.0001) and
9-fold increase (P < 0.0001) in total light emissions and
light emissions corrected for fetoplacental mass, respec-
tively, indicating a large increase in fetoplacental Vegfr2
activity with the advancement of gestation. Expression
of Vegfr2 is induced by increased activity of VEGF [27],
a powerful pro-angiogenic factor, suggesting that the
increase in fetoplacental light emissions observed in the
current study represents the angiogenic activity asso-
ciated with the tremendous growth of the fetoplacental
vasculature network and fetus [24-26] during this per-
iod. By monitoring the transcriptional activity of Vegfr2
using the luciferase reporter gene and bioluminescent
imaging, the current approach affords the capability to
study late gestation fetoplacental angiogenesis from a
molecular standpoint in a non-invasive, quantitative,
and longitudinal manner in vivo. Moreover, the results
are in agreement with previous work demonstrating the
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Figure 3 In vivo and ex vivo bioluminescent imaging and RT-PCR analysis of Vegfr2 in fetoplacental tissues. Figures represent
bioluminescent imaging of fetoplacental Vegfr2 activity (a) in vivo in a pregnant mouse, (b) ex vivo in a gravid uterus (inset bright field image),
and (c) ex vivo in a whole FPU (inset bright field image) from a single pregnancy at gestational day (GD) 16. Additionally, (d) RT-PCR analysis
revealed that Vegfr2 mRNA was present and increased in the whole FPU during GD 12 to 18.
a,b,c means without a common superscript differ
(P ≤ 0.05).* means tended to differ (P < 0.10).
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Page 6 of 9marked increase in angiogenic activity occurring during
the latter third of gestation in mice [24,25], suggesting
the usefulness of this approach for monitoring fetopla-
cental angiogenic activity during this period.
We also report a serendipitous, yet interesting, finding in
which a dramatic decline in light emissions was associated
with a poor outcome in a seventh pregnancy (Figure 4a).
During the imaging period for one mouse, light emissions
remained minimal and similar to background measure-
ments on GD 12 and 13, indicating a weak signal. Light
emissions increased above background measurements on
GD 14 and 15. However on GD 16, there was a four-fold
decrease in light emissions, followed by a continuing
decline on GD 17 and 18 of gestation. Interestingly, the
decline in light emissions was associated with a poor preg-
nancy outcome in which there were no surviving offspring.
Previous studies have revealed that VEGFR2 and VEGF
are vital for fetal development and survival [3,5,9]. More-
over, Ferrara and colleagues speculated that if Vegf activity
during pregnancy decreases to a critical point, organogen-
esis may be permanently impaired [5]. This may suggest
that the observed decline in Vegfr2 gene activity in the
current study was associated with a compromised preg-
nancy that resulted in fetal demise, or the decline in light
emissions could be simply the result of fetal death rather
than fetal death stemming from an angiogenic defect.
Either way, this unexpected observation further highlights
the importance of VEGFR2 during pregnancy and demon-
strates that the current approach could be utilized to
evaluate pregnancy loss resulting from inactivation of
angiogenic pathways.
The approach detailed in the current study offers a
novel method for studying late gestational angiogenesis
in mice. However, anesthetizing pregnant mice poses
some concern for the developing fetuses. While isofluor-
ane exposure has been reported to have a deleterious
effect on early mouse embryo development [28], recent
reports have demonstrated that fetal exposure to iso-
fluorane during ultrasonography on GD 8.5 or GD 10.5
has no significant adverse biological effects [29], which
is consistent with the lack of negative effects observed
in the current study. Given that the model described
herein requires the use of isofluorane during late gesta-
tion, perhaps the deleterious effects that isofluorane has
on early mouse embryo development were avoided.
However, it cannot be fully determined whether iso-
fluorane anesthesia contributed to the pregnancy demise
in the seventh mouse.
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Figure 4 Bioluminescent imaging of Vegfr2 activity in failed pregnancy and Vegfr2-luc neonates.( a) Minimal signal was detected on
gestational day (GD) 12 and 13. Light emission increased on GD 14 and 15; however, light emission drastically declined on GD 16, 17, and 18.
This decrease in light emissions was associated with a poor pregnancy outcome, in which there were no surviving offspring. (b) Light emissions
were detected in the neonates, and from PND 7 to 21, there was an 83-fold reduction in light emissions (P < 0.0001), indicating a decrease in
Vegfr2 gene expression as the neonates progressed in development. The inserted graph depicts the increase in average pup weight (P < 0.0001)
occurring during this period as an indicator of growth. The images are a representative group of animals imaged during this period.
a,b,c means
without a common superscript differ (P ≤ 0.05).
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Angiogenesis is a developmental process that becomes
relatively quiescent in adulthood except during certain
conditions such as tumor development [30], wound heal-
ing [31] and corpus luteum development [19]. However,
angiogenesis, and thus Vegf and Vegfr2 activity, are extre-
mely important during the neonatal period with activity
declining with age [21,32]. Neonatal mice (n = 27) from
six pregnancies were imaged at PND 7, 14 and 21 to
monitor Vegfr2 gene activity during postnatal develop-
ment. Bioluminescent signal was detected at PND 7, 14
and 21 and differed over the imaging period (P < 0.0001;
Figure 4b). From PND 7 to 14, there was a 11.7-fold
decrease in light emissions (P < 0.0001), followed by a ten-
dency for a 7-fold decrease in light emissions from PND
14 to 21 (P = 0.08). Overall, there was an 83-fold reduction
in light emissions from PND 7 to 21 (P < 0.0001), indicat-
ing a decrease in Vegfr2 gene expression and, thus, angio-
genesis as the neonates progressed in development. While
the decline of Vegfr2 activity during the neonatal period is
not a novel observation [11,21], the approach described in
this study offers continuous monitoring of Vegfr2 activity
during the latter third of gestation and subsequent neona-
tal development within the same animals.
Conclusions
In the current study, the usefulness of the Vegfr2-luc mouse
as a research model to measure fetoplacental Vegfr2 gene
activity in vivo was assessed and determined to be effective
using bioluminescent imaging. Light emissions, representa-
tive of fetoplacental Vegfr2 gene activity, were detected on
GD 12 to 18, monitored quantitatively and longitudinally
during this period, and were consistent with traditional
end-point molecular analysis. This novel approach offers
the ability to obtain meaningful data depicting changes in
fetoplacental Vegfr2 activity in utero. Neonatal Vegfr2 activ-
ity was also monitored in the resultant offspring during the
first three weeks of life. Accordingly, this approach may
have great potential for studying developmental perturba-
tions encountered in utero and how they may influence late
fetal and early postnatal angiogenesis.
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